AAAAAA

   
Results: 1-12 |
Results: 12
Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis
Authors: Bolon, B Carter, C Daris, M Morony, S Capparelli, C Hsieh, A Mao, MF Kostenuik, P Dunstan, CR Lacey, DL Sheng, JZ
Citation: B. Bolon et al., Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis, MOL THER, 3(2), 2001, pp. 197-205
OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats
Authors: Kostenuik, PJ Capparelli, C Morony, S Adamu, S Shimamoto, G Shen, V Lacey, DL Dunstan, CR
Citation: Pj. Kostenuik et al., OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats, ENDOCRINOL, 142(10), 2001, pp. 4295-4304
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden insyngeneic and nude mouse models of experimental bone metastasis
Authors: Morony, S Capparelli, C Sarosi, I Lacey, DL Dunstan, CR Kostenuik, PJ
Citation: S. Morony et al., Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden insyngeneic and nude mouse models of experimental bone metastasis, CANCER RES, 61(11), 2001, pp. 4432-4436
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
Authors: Li, J Sarosi, I Yan, XQ Morony, S Capparelli, C Tan, HL McCabe, S Elliott, R Scully, S Van, G Kaufman, S Juan, SC Sun, Y Tarpley, J Martin, L Christensen, K McCabe, J Kostenuik, P Hsu, H Fletcher, F Dunstan, CR Lacey, DL Boyle, WJ
Citation: J. Li et al., RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism, P NAS US, 97(4), 2000, pp. 1566-1571
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis
Authors: Min, H Morony, S Sarosi, I Dunstan, CR Capparelli, C Scully, S Van, G Kaufman, S Kostenuik, PJ Lacey, DL Boyle, TJ Simonet, WS
Citation: H. Min et al., Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis, J EXP MED, 192(4), 2000, pp. 463-474
Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
Authors: Capparelli, C Kostenuik, PJ Morony, S Starnes, C Weimann, B Van, G Scully, S Qi, MY Lacey, DL Dunstan, CR
Citation: C. Capparelli et al., Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy, CANCER RES, 60(4), 2000, pp. 783-787
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
Authors: Lomaga, MA Yeh, WC Sarosi, I Duncan, GS Furlonger, C Ho, A Morony, S Capparelli, C Van, G Kaufman, S van der Heiden, A Itie, A Wakeham, A Khoo, W Sasaki, T Cao, ZD Penninger, JM Paige, CJ Lacey, DL Dunstan, CR Boyle, WJ Goeddel, DV Mak, TW
Citation: Ma. Lomaga et al., TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling, GENE DEV, 13(8), 1999, pp. 1015-1024
A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1 beta, TNF-alpha, PTH, PTHrP, and 1,25(OH)(2)D-3
Authors: Morony, S Capparelli, C Lee, R Shimamoto, G Boone, T Lacey, DL Dunstan, CR
Citation: S. Morony et al., A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1 beta, TNF-alpha, PTH, PTHrP, and 1,25(OH)(2)D-3, J BONE MIN, 14(9), 1999, pp. 1478-1485
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
Authors: Kong, YY Feige, U Sarosi, I Bolon, B Tafuri, A Morony, S Capparelli, C Li, J Elliott, R McCabe, S Wong, T Campagnuolo, G Moran, E Bogoch, ER Van, G Nguyen, LT Ohashi, PS Lacey, DL Fish, E Boyle, WJ Penninger, JM
Citation: Yy. Kong et al., Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand, NATURE, 402(6759), 1999, pp. 304-309
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
Authors: Kong, YY Yoshida, H Sarosi, I Tan, HL Timms, E Capparelli, C Morony, S Oliveira-dos-Santos, AJ Van, G Itie, A Khoo, W Wakeham, A Dunstan, CR Lacey, DL Mak, TW Boyle, WJ Penninger, JM
Citation: Yy. Kong et al., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, NATURE, 397(6717), 1999, pp. 315-323
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
Authors: Hsu, HL Lacey, DL Dunstan, CR Solovyev, I Colombero, A Timms, E Tan, HL Elliott, G Kelley, MJ Sarosi, I Wang, L Xia, XZ Elliott, R Chiu, L Black, T Scully, S Capparelli, C Morony, S Shimamoto, G Bass, MB Boyle, WJ
Citation: Hl. Hsu et al., Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand, P NAS US, 96(7), 1999, pp. 3540-3545
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
Authors: Burgess, TL Qian, YX Kaufman, S Ring, BD Van, G Capparelli, C Kelley, M Hsu, HL Boyle, WJ Dunstan, CR Hu, S Lacey, DL
Citation: Tl. Burgess et al., The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts, J CELL BIOL, 145(3), 1999, pp. 527-538
Risultati: 1-12 |